First-in-Human Trial of NRTX-1001 GABAergic Interneuron Cell Therapy for Focal Epilepsy - Updated Clinical Trial Results (P8-9.003)

To present updated findings from a first-in-human, open-label study of NRTX-1001, an allogeneic GABAergic interneuron therapy, for unilateral drug-resistant temporal lobe epilepsy with mesial temporal sclerosis (NCT05135091).